Daily Wire host Matt Walsh said parents have to be proactive in their children’s lives and on guard against transgender ideology.
Walsh appeared on Sen. Marsha Blackburn‘s (R-TN) show “Unmuted With Marsha” on Wednesday to discuss the “social contagion” caused by transgender ideology. Walsh’s appearance comes after he reported last week that Vanderbilt University Medical Center provides transgender surgeries and treatments to minors.
The Tennessee Republican asked Walsh about his advice for parents concerned that their own children may be swept up in the contagion and begin questioning whether they are actually boys or girls.
“As a parent of four kids myself, two on the way, that it feels sort of overwhelming how you’re supposed to protect your kids from it,” Walsh said. “There are things that you can do. For one thing, what I would certainly recommend is that you don’t just give your kid a smart phone with unfettered access to the internet where they can access all of these sites and everything where these ideas are promulgated.”
Walsh called social media a “delivery mechanism for the social contagion of gender ideology.”
The Daily Wire host said that parents who place their children in public schools must be extra vigilant about what their children are being exposed to in the classroom.
“You need to be very involved at school board meetings, PTA, I mean you need to be asking questions about what kids are being taught. Talk to your kid every day after school to find out what they were taught,” he said.
The same level of attention should be placed on your children’s doctors, therapists, counselors, and others with significant influence on the child.
“It’s not that you can’t bring your kids to any of those places, but you have to realize that this ideology is present everywhere and so you have to ask questions,” Walsh said.
Last week, Blackburn joined with Sen. Cynthia Lummis (R-WY) to write a letter to FDA Commissioner Robert Califf about the side effects of gonadotropin-releasing hormone (GnRH) agonists, which are used to treat minors with early-onset puberty as well as stave off the normal pubescent development of minors who may be considering sex-reassignment surgery.
The senators noted that while GnRH agonists are approved for use by patients with developmental disorders such as central precocious puberty (CPP), which makes a child experience puberty younger than normal, the drug is not approved by the FDA for gender dysphoric or transgender treatment.
“[T]he off-label use of GnRH agonists in connection with diagnoses of gender dysphoria or the provision of transgender care is, by definition, intended to suppress the normal biological processes of puberty beyond the normal age of onset. Given that such off-label use deliberately delays and alters normal development, We are deeply concerned that it could result in significant short-term and long-term risks and adverse effects on adolescent patients,” the senators wrote.
